Market closed
Profound Medical/$PROF
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Profound Medical
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Ticker
$PROF
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Mississauga, Canada
Employees
131
Website
Profound Medical Metrics
BasicAdvanced
$189M
Market cap
-
P/E ratio
-$1.33
EPS
0.83
Beta
-
Dividend rate
Price and volume
Market cap
$189M
Beta
0.83
52-week high
$11.42
52-week low
$7.11
Average daily volume
40K
Financial strength
Current ratio
6.123
Quick ratio
5.115
Long term debt to equity
12.114
Total debt to equity
20.049
Interest coverage (TTM)
-48.87%
Management effectiveness
Return on assets (TTM)
-44.62%
Return on equity (TTM)
-90.17%
Valuation
Price to revenue (TTM)
20.255
Price to book
8.49
Price to tangible book (TTM)
8.59
Price to free cash flow (TTM)
-7.329
Growth
Revenue change (TTM)
39.35%
Earnings per share change (TTM)
-4.28%
3-year revenue growth (CAGR)
0.86%
3-year earnings per share growth (CAGR)
-1.53%
What the Analysts think about Profound Medical
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Profound Medical stock.
Profound Medical Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Profound Medical Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Profound Medical News
AllArticlesVideos
Profound Medical Corporation (PROF) Q3 2024 Earnings Call Transcript
Seeking Alpha·2 weeks ago
Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025
GlobeNewsWire·2 weeks ago
Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Profound Medical stock?
Profound Medical (PROF) has a market cap of $189M as of November 21, 2024.
What is the P/E ratio for Profound Medical stock?
The price to earnings (P/E) ratio for Profound Medical (PROF) stock is 0 as of November 21, 2024.
Does Profound Medical stock pay dividends?
No, Profound Medical (PROF) stock does not pay dividends to its shareholders as of November 21, 2024.
When is the next Profound Medical dividend payment date?
Profound Medical (PROF) stock does not pay dividends to its shareholders.
What is the beta indicator for Profound Medical?
Profound Medical (PROF) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.